Loading…

Atogepant Is Not Associated With Clinically Meaningful Alanine Aminotransferase Elevations in Healthy Adults

Atogepant is a potent, selective, oral calcitonin gene–related peptide (CGRP) receptor antagonist in development for migraine prevention. The chemical structure of atogepant is distinct from previous CGRP receptor antagonists, which were associated with elevated serum alanine aminotransferase (ALT)...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and translational science 2021-03, Vol.14 (2), p.599-605
Main Authors: Min, K. Chris, Kraft, Walter K., Bondiskey, Phung, Colón‐González, Francheska, Liu, Wen, Xu, Jialin, Panebianco, Deborah, Mixson, Lori, Dockendorf, Marissa F., Matthews, Catherine Z., Boinpally, Ramesh
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c5097-5a385236882ed7d6510f990367d00022a8d8651ee1c5acafc4a2b4e5b6d11a233
cites cdi_FETCH-LOGICAL-c5097-5a385236882ed7d6510f990367d00022a8d8651ee1c5acafc4a2b4e5b6d11a233
container_end_page 605
container_issue 2
container_start_page 599
container_title Clinical and translational science
container_volume 14
creator Min, K. Chris
Kraft, Walter K.
Bondiskey, Phung
Colón‐González, Francheska
Liu, Wen
Xu, Jialin
Panebianco, Deborah
Mixson, Lori
Dockendorf, Marissa F.
Matthews, Catherine Z.
Boinpally, Ramesh
description Atogepant is a potent, selective, oral calcitonin gene–related peptide (CGRP) receptor antagonist in development for migraine prevention. The chemical structure of atogepant is distinct from previous CGRP receptor antagonists, which were associated with elevated serum alanine aminotransferase (ALT) in clinical trials. Here, we report the safety, tolerability, and pharmacokinetics (PKs) of a once‐daily supratherapeutic dose (170 mg) of atogepant for 28 days from a randomized, double‐blind, placebo‐controlled phase I trial in healthy participants. Overall safety, hepatic safety, and plasma PK parameters were evaluated. Thirty‐four participants aged 23–55 years enrolled; 28 (82.4%) completed the study in accordance with the protocol. Multiple doses of 170 mg atogepant for 28 consecutive days were generally well‐tolerated. All adverse events (AEs; reported in 87.0% of the atogepant group; 72.7%, placebo) were mild in severity except one serious AE of subarachnoid hemorrhage due to a bicycle accident and not considered related to treatment. There were two discontinuations due to AEs, both with atogepant, one considered possibly related to treatment. Over 28 days of treatment, no participant receiving atogepant had an ALT elevation above 1.5 × upper limit of normal. Change from baseline in serum ALT levels was not different between atogepant and placebo. Atogepant is rapidly absorbed (median time to maximum plasma concentration, ~ 2 hours) with an apparent terminal half‐life of ~ 11 hours, and no evidence of accumulation after once‐daily dosing. Overall, atogepant at a high oral dose is safe and well‐tolerated in healthy participants with no clinically meaningful elevations in ALT.
doi_str_mv 10.1111/cts.12917
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_deebdb740c1e4f7f9119fa5f137047fd</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_deebdb740c1e4f7f9119fa5f137047fd</doaj_id><sourcerecordid>2504793580</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5097-5a385236882ed7d6510f990367d00022a8d8651ee1c5acafc4a2b4e5b6d11a233</originalsourceid><addsrcrecordid>eNp1kc9vFCEUxydGY3_owX_AkHjysC0wwzBzMZlsartJ1YM1HgkDj102LKzA1Ox_L-3UjT3IBfL45PPey7eq3hF8Qcq5VDldENoT_qI6JZzRRYdb-vL4Zs1JdZbSFuO2bjv2ujqpa9JQTJrTyg05rGEvfUarhL6GjIaUgrIyg0Y_bd6gpbPeKuncAX0B6a1fm8mhwT08AQ0760OO0icDUSZAVw7uZbbBJ2Q9ugHp8uaABj25nN5Ur4x0Cd4-3efVj89Xd8ubxe2369VyuF0ohnu-YLLuGC2jdhQ01y0j2PQ9rluuMcaUyk53pQhAFJNKGtVIOjbAxlYTImldn1er2auD3Ip9tDsZDyJIKx4LIa6FjNkqB0IDjHrkDVYEGsNNT0hvJDOk5rjhRhfXp9m1n8YdaAW-bOueSZ__eLsR63AveN_XlHdF8OFJEMOvCVIW2zBFX_YXlJUefc06XKiPM6ViSCmCOXYgWDyELErI4jHkwr7_d6Qj-TfVAlzOwG_r4PB_k1jefZ-VfwAGorJ-</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2504793580</pqid></control><display><type>article</type><title>Atogepant Is Not Associated With Clinically Meaningful Alanine Aminotransferase Elevations in Healthy Adults</title><source>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</source><source>Open Access: Wiley-Blackwell Open Access Journals</source><source>PubMed Central Free</source><creator>Min, K. Chris ; Kraft, Walter K. ; Bondiskey, Phung ; Colón‐González, Francheska ; Liu, Wen ; Xu, Jialin ; Panebianco, Deborah ; Mixson, Lori ; Dockendorf, Marissa F. ; Matthews, Catherine Z. ; Boinpally, Ramesh</creator><creatorcontrib>Min, K. Chris ; Kraft, Walter K. ; Bondiskey, Phung ; Colón‐González, Francheska ; Liu, Wen ; Xu, Jialin ; Panebianco, Deborah ; Mixson, Lori ; Dockendorf, Marissa F. ; Matthews, Catherine Z. ; Boinpally, Ramesh</creatorcontrib><description>Atogepant is a potent, selective, oral calcitonin gene–related peptide (CGRP) receptor antagonist in development for migraine prevention. The chemical structure of atogepant is distinct from previous CGRP receptor antagonists, which were associated with elevated serum alanine aminotransferase (ALT) in clinical trials. Here, we report the safety, tolerability, and pharmacokinetics (PKs) of a once‐daily supratherapeutic dose (170 mg) of atogepant for 28 days from a randomized, double‐blind, placebo‐controlled phase I trial in healthy participants. Overall safety, hepatic safety, and plasma PK parameters were evaluated. Thirty‐four participants aged 23–55 years enrolled; 28 (82.4%) completed the study in accordance with the protocol. Multiple doses of 170 mg atogepant for 28 consecutive days were generally well‐tolerated. All adverse events (AEs; reported in 87.0% of the atogepant group; 72.7%, placebo) were mild in severity except one serious AE of subarachnoid hemorrhage due to a bicycle accident and not considered related to treatment. There were two discontinuations due to AEs, both with atogepant, one considered possibly related to treatment. Over 28 days of treatment, no participant receiving atogepant had an ALT elevation above 1.5 × upper limit of normal. Change from baseline in serum ALT levels was not different between atogepant and placebo. Atogepant is rapidly absorbed (median time to maximum plasma concentration, ~ 2 hours) with an apparent terminal half‐life of ~ 11 hours, and no evidence of accumulation after once‐daily dosing. Overall, atogepant at a high oral dose is safe and well‐tolerated in healthy participants with no clinically meaningful elevations in ALT.</description><identifier>ISSN: 1752-8054</identifier><identifier>EISSN: 1752-8062</identifier><identifier>DOI: 10.1111/cts.12917</identifier><identifier>PMID: 33142014</identifier><language>eng</language><publisher>United States: John Wiley &amp; Sons, Inc</publisher><subject>Adults ; Adverse events ; Alanine ; Alanine transaminase ; Blood &amp; organ donations ; Calcitonin ; Calcitonin gene-related peptide ; Clinical trials ; Dosage ; Drug dosages ; FDA approval ; Headache ; Liver ; Migraine ; Monoclonal antibodies ; Peptides ; Pharmacokinetics ; Placebos ; Plasma ; Prevention ; Safety ; Subarachnoid hemorrhage</subject><ispartof>Clinical and translational science, 2021-03, Vol.14 (2), p.599-605</ispartof><rights>2020 Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc. published by Wiley Periodicals LLC on behalf of the American Society for Clinical Pharmacology and Therapeutics.</rights><rights>2020 Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of the American Society for Clinical Pharmacology and Therapeutics.</rights><rights>2021. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5097-5a385236882ed7d6510f990367d00022a8d8651ee1c5acafc4a2b4e5b6d11a233</citedby><cites>FETCH-LOGICAL-c5097-5a385236882ed7d6510f990367d00022a8d8651ee1c5acafc4a2b4e5b6d11a233</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2504793580/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2504793580?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,11562,25753,27924,27925,37012,44590,46052,46476,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33142014$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Min, K. Chris</creatorcontrib><creatorcontrib>Kraft, Walter K.</creatorcontrib><creatorcontrib>Bondiskey, Phung</creatorcontrib><creatorcontrib>Colón‐González, Francheska</creatorcontrib><creatorcontrib>Liu, Wen</creatorcontrib><creatorcontrib>Xu, Jialin</creatorcontrib><creatorcontrib>Panebianco, Deborah</creatorcontrib><creatorcontrib>Mixson, Lori</creatorcontrib><creatorcontrib>Dockendorf, Marissa F.</creatorcontrib><creatorcontrib>Matthews, Catherine Z.</creatorcontrib><creatorcontrib>Boinpally, Ramesh</creatorcontrib><title>Atogepant Is Not Associated With Clinically Meaningful Alanine Aminotransferase Elevations in Healthy Adults</title><title>Clinical and translational science</title><addtitle>Clin Transl Sci</addtitle><description>Atogepant is a potent, selective, oral calcitonin gene–related peptide (CGRP) receptor antagonist in development for migraine prevention. The chemical structure of atogepant is distinct from previous CGRP receptor antagonists, which were associated with elevated serum alanine aminotransferase (ALT) in clinical trials. Here, we report the safety, tolerability, and pharmacokinetics (PKs) of a once‐daily supratherapeutic dose (170 mg) of atogepant for 28 days from a randomized, double‐blind, placebo‐controlled phase I trial in healthy participants. Overall safety, hepatic safety, and plasma PK parameters were evaluated. Thirty‐four participants aged 23–55 years enrolled; 28 (82.4%) completed the study in accordance with the protocol. Multiple doses of 170 mg atogepant for 28 consecutive days were generally well‐tolerated. All adverse events (AEs; reported in 87.0% of the atogepant group; 72.7%, placebo) were mild in severity except one serious AE of subarachnoid hemorrhage due to a bicycle accident and not considered related to treatment. There were two discontinuations due to AEs, both with atogepant, one considered possibly related to treatment. Over 28 days of treatment, no participant receiving atogepant had an ALT elevation above 1.5 × upper limit of normal. Change from baseline in serum ALT levels was not different between atogepant and placebo. Atogepant is rapidly absorbed (median time to maximum plasma concentration, ~ 2 hours) with an apparent terminal half‐life of ~ 11 hours, and no evidence of accumulation after once‐daily dosing. Overall, atogepant at a high oral dose is safe and well‐tolerated in healthy participants with no clinically meaningful elevations in ALT.</description><subject>Adults</subject><subject>Adverse events</subject><subject>Alanine</subject><subject>Alanine transaminase</subject><subject>Blood &amp; organ donations</subject><subject>Calcitonin</subject><subject>Calcitonin gene-related peptide</subject><subject>Clinical trials</subject><subject>Dosage</subject><subject>Drug dosages</subject><subject>FDA approval</subject><subject>Headache</subject><subject>Liver</subject><subject>Migraine</subject><subject>Monoclonal antibodies</subject><subject>Peptides</subject><subject>Pharmacokinetics</subject><subject>Placebos</subject><subject>Plasma</subject><subject>Prevention</subject><subject>Safety</subject><subject>Subarachnoid hemorrhage</subject><issn>1752-8054</issn><issn>1752-8062</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp1kc9vFCEUxydGY3_owX_AkHjysC0wwzBzMZlsartJ1YM1HgkDj102LKzA1Ox_L-3UjT3IBfL45PPey7eq3hF8Qcq5VDldENoT_qI6JZzRRYdb-vL4Zs1JdZbSFuO2bjv2ujqpa9JQTJrTyg05rGEvfUarhL6GjIaUgrIyg0Y_bd6gpbPeKuncAX0B6a1fm8mhwT08AQ0760OO0icDUSZAVw7uZbbBJ2Q9ugHp8uaABj25nN5Ur4x0Cd4-3efVj89Xd8ubxe2369VyuF0ohnu-YLLuGC2jdhQ01y0j2PQ9rluuMcaUyk53pQhAFJNKGtVIOjbAxlYTImldn1er2auD3Ip9tDsZDyJIKx4LIa6FjNkqB0IDjHrkDVYEGsNNT0hvJDOk5rjhRhfXp9m1n8YdaAW-bOueSZ__eLsR63AveN_XlHdF8OFJEMOvCVIW2zBFX_YXlJUefc06XKiPM6ViSCmCOXYgWDyELErI4jHkwr7_d6Qj-TfVAlzOwG_r4PB_k1jefZ-VfwAGorJ-</recordid><startdate>202103</startdate><enddate>202103</enddate><creator>Min, K. Chris</creator><creator>Kraft, Walter K.</creator><creator>Bondiskey, Phung</creator><creator>Colón‐González, Francheska</creator><creator>Liu, Wen</creator><creator>Xu, Jialin</creator><creator>Panebianco, Deborah</creator><creator>Mixson, Lori</creator><creator>Dockendorf, Marissa F.</creator><creator>Matthews, Catherine Z.</creator><creator>Boinpally, Ramesh</creator><general>John Wiley &amp; Sons, Inc</general><general>John Wiley and Sons Inc</general><general>Wiley</general><scope>24P</scope><scope>WIN</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7T5</scope><scope>7TK</scope><scope>7TM</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M7N</scope><scope>M7P</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>RC3</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>202103</creationdate><title>Atogepant Is Not Associated With Clinically Meaningful Alanine Aminotransferase Elevations in Healthy Adults</title><author>Min, K. Chris ; Kraft, Walter K. ; Bondiskey, Phung ; Colón‐González, Francheska ; Liu, Wen ; Xu, Jialin ; Panebianco, Deborah ; Mixson, Lori ; Dockendorf, Marissa F. ; Matthews, Catherine Z. ; Boinpally, Ramesh</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5097-5a385236882ed7d6510f990367d00022a8d8651ee1c5acafc4a2b4e5b6d11a233</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adults</topic><topic>Adverse events</topic><topic>Alanine</topic><topic>Alanine transaminase</topic><topic>Blood &amp; organ donations</topic><topic>Calcitonin</topic><topic>Calcitonin gene-related peptide</topic><topic>Clinical trials</topic><topic>Dosage</topic><topic>Drug dosages</topic><topic>FDA approval</topic><topic>Headache</topic><topic>Liver</topic><topic>Migraine</topic><topic>Monoclonal antibodies</topic><topic>Peptides</topic><topic>Pharmacokinetics</topic><topic>Placebos</topic><topic>Plasma</topic><topic>Prevention</topic><topic>Safety</topic><topic>Subarachnoid hemorrhage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Min, K. Chris</creatorcontrib><creatorcontrib>Kraft, Walter K.</creatorcontrib><creatorcontrib>Bondiskey, Phung</creatorcontrib><creatorcontrib>Colón‐González, Francheska</creatorcontrib><creatorcontrib>Liu, Wen</creatorcontrib><creatorcontrib>Xu, Jialin</creatorcontrib><creatorcontrib>Panebianco, Deborah</creatorcontrib><creatorcontrib>Mixson, Lori</creatorcontrib><creatorcontrib>Dockendorf, Marissa F.</creatorcontrib><creatorcontrib>Matthews, Catherine Z.</creatorcontrib><creatorcontrib>Boinpally, Ramesh</creatorcontrib><collection>Open Access: Wiley-Blackwell Open Access Journals</collection><collection>Wiley Free Content</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>ProQuest Biological Science Journals</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Genetics Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Clinical and translational science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Min, K. Chris</au><au>Kraft, Walter K.</au><au>Bondiskey, Phung</au><au>Colón‐González, Francheska</au><au>Liu, Wen</au><au>Xu, Jialin</au><au>Panebianco, Deborah</au><au>Mixson, Lori</au><au>Dockendorf, Marissa F.</au><au>Matthews, Catherine Z.</au><au>Boinpally, Ramesh</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Atogepant Is Not Associated With Clinically Meaningful Alanine Aminotransferase Elevations in Healthy Adults</atitle><jtitle>Clinical and translational science</jtitle><addtitle>Clin Transl Sci</addtitle><date>2021-03</date><risdate>2021</risdate><volume>14</volume><issue>2</issue><spage>599</spage><epage>605</epage><pages>599-605</pages><issn>1752-8054</issn><eissn>1752-8062</eissn><abstract>Atogepant is a potent, selective, oral calcitonin gene–related peptide (CGRP) receptor antagonist in development for migraine prevention. The chemical structure of atogepant is distinct from previous CGRP receptor antagonists, which were associated with elevated serum alanine aminotransferase (ALT) in clinical trials. Here, we report the safety, tolerability, and pharmacokinetics (PKs) of a once‐daily supratherapeutic dose (170 mg) of atogepant for 28 days from a randomized, double‐blind, placebo‐controlled phase I trial in healthy participants. Overall safety, hepatic safety, and plasma PK parameters were evaluated. Thirty‐four participants aged 23–55 years enrolled; 28 (82.4%) completed the study in accordance with the protocol. Multiple doses of 170 mg atogepant for 28 consecutive days were generally well‐tolerated. All adverse events (AEs; reported in 87.0% of the atogepant group; 72.7%, placebo) were mild in severity except one serious AE of subarachnoid hemorrhage due to a bicycle accident and not considered related to treatment. There were two discontinuations due to AEs, both with atogepant, one considered possibly related to treatment. Over 28 days of treatment, no participant receiving atogepant had an ALT elevation above 1.5 × upper limit of normal. Change from baseline in serum ALT levels was not different between atogepant and placebo. Atogepant is rapidly absorbed (median time to maximum plasma concentration, ~ 2 hours) with an apparent terminal half‐life of ~ 11 hours, and no evidence of accumulation after once‐daily dosing. Overall, atogepant at a high oral dose is safe and well‐tolerated in healthy participants with no clinically meaningful elevations in ALT.</abstract><cop>United States</cop><pub>John Wiley &amp; Sons, Inc</pub><pmid>33142014</pmid><doi>10.1111/cts.12917</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1752-8054
ispartof Clinical and translational science, 2021-03, Vol.14 (2), p.599-605
issn 1752-8054
1752-8062
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_deebdb740c1e4f7f9119fa5f137047fd
source Publicly Available Content Database (Proquest) (PQ_SDU_P3); Open Access: Wiley-Blackwell Open Access Journals; PubMed Central Free
subjects Adults
Adverse events
Alanine
Alanine transaminase
Blood & organ donations
Calcitonin
Calcitonin gene-related peptide
Clinical trials
Dosage
Drug dosages
FDA approval
Headache
Liver
Migraine
Monoclonal antibodies
Peptides
Pharmacokinetics
Placebos
Plasma
Prevention
Safety
Subarachnoid hemorrhage
title Atogepant Is Not Associated With Clinically Meaningful Alanine Aminotransferase Elevations in Healthy Adults
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T21%3A29%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Atogepant%20Is%20Not%20Associated%20With%20Clinically%20Meaningful%20Alanine%20Aminotransferase%20Elevations%20in%20Healthy%20Adults&rft.jtitle=Clinical%20and%20translational%20science&rft.au=Min,%20K.%20Chris&rft.date=2021-03&rft.volume=14&rft.issue=2&rft.spage=599&rft.epage=605&rft.pages=599-605&rft.issn=1752-8054&rft.eissn=1752-8062&rft_id=info:doi/10.1111/cts.12917&rft_dat=%3Cproquest_doaj_%3E2504793580%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5097-5a385236882ed7d6510f990367d00022a8d8651ee1c5acafc4a2b4e5b6d11a233%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2504793580&rft_id=info:pmid/33142014&rfr_iscdi=true